SHORT REVIEW
COVID-19 associated Aspergillosis
More details
Hide details
1 |
Internist – Intensivist, Consultant,
Department of Emergency Medicine,
University Hospital ATTIKON, Athens, Greece |
2 |
Professor Critical Care Medicine
Department of Critical Care Medicine,
University Hospital ATTIKON, Athens, Greece |
CORRESPONDING AUTHOR
Maria Panagiota Almyroudi
Department of Emergency Medicine,
“Attikon” University Hospital, School of Medicine,
National and Kapodistrian University of Athens,
1 Rimini Street, 12462, Haidari, Greece
Pneumon 2020;33(2):1–4
KEYWORDS
ABSTRACT
Invasive pulmonary aspergillosis (IPA) may complicate severe COVID-19 patients. The incidence, although is not well confirmed, varies (20-35%) and the already recognized host factors for IPA in immunosuppressed patients are not identified in non-immunocompromised patients with COVID-19 associated pulmonary aspergillosis (CAPA). Additionally, clinical characteristics and radiological findings are not specific. Given the probable high burden of the co-infection, a screening diagnostic work-up, including serum and BAL galactomannan measurement, fungal cultures of upper and lower respiratory tract samples are considered mandatory in all mechanically ventilated patients with COVID-19.
ABBREVIATIONS
IPA: Invasive pulmonary aspergillosis,
CAPA: COVID-19 associated pulmonary aspergillosis,
BAL: bronchoalveolar lavage
CONFLICTS OF INTEREST
None
REFERENCES (11)
1.
Flikweert AW, Grootenboers MJJH, Yick DCY et al. Late histopathologic characteristics of critically ill COVID-19 patients: Different phenotypes without evidence of invasive aspergillosis, a case series. J Crit Care 2020, 59:149–55.
2.
Verweij PE, Rijnders BJA, Brüggemann RJM et al. Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion. Intensive Care Med 2020, 22:1–12.
3.
van Arkel ALE, Rijpstra TA, Belderbos HNA, van Wijngaarden P, Verweij PE, Bentvelsen RG. COVID-19–associated Pulmonary Aspergillosis. Am J Respir Crit Care Med 2020, 202:132–5.
4.
Alexandre Alanio, Sarah Dellière, Sofiane Fodil, Stéphane Bretagne, and Bruno Mégarbanec. Prevalence of putative invasive pulmonary aspergillosis in critically ill patients with COVID-19. Lancet Respir Med 2020, 8:e48–e49.
5.
Blot SI, Taccone F-S, Van den Abeele A-M et al; Asp ICU Study Investigators. A clinical algorithm to diagnose invasive pulmonary aspergillosis in critically ill patients. Am J Respir Crit Care Med 2012, 186:56-64.
6.
Rutsaert L, Steinfort N, Van Hunsel T, et al. COVID-19-associated invasive pulmonary aspergillosis. Ann Intensive Care 2020, 10:71.
7.
Koehler P, Cornely OA, Böttiger BW et al. COVID‐19 associated pulmonary aspergillosis. Mycoses 2020, 63:528–34.
8.
Bruno G, Fabrizio C, Buccolieroa GB. COVID-19-associated pulmonary aspergillosis: adding insult to injury. Lancet Microbe 2020, 1:e106.
9.
Gangneux J-P, Bougnoux M-E, Cornet DM, JR Zahar. Invasive fungal diseases during COVID-19: We should be prepared. J Mycol Med 2020, 30:100971.
10.
Δημόπουλος Γ, Καραμπίνης Α. Μυκητιασικές λοιμώξεις στη Mονάδα Eντατικής Θεραπείας. Πνεύμων 2002, 15:14-30.
11.
Verweij PE, Gangneux J-P, Bassetti M, et al. Diagnosing COVID19-associated pulmonary aspergillosis. Lancet Microbe 2020, 1:e53–e55.